NO20002279L - Sammensetninger av lipidsenkende midler - Google Patents
Sammensetninger av lipidsenkende midlerInfo
- Publication number
- NO20002279L NO20002279L NO20002279A NO20002279A NO20002279L NO 20002279 L NO20002279 L NO 20002279L NO 20002279 A NO20002279 A NO 20002279A NO 20002279 A NO20002279 A NO 20002279A NO 20002279 L NO20002279 L NO 20002279L
- Authority
- NO
- Norway
- Prior art keywords
- lipid
- lowering agents
- compositions
- melt
- day
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000003524 antilipemic agent Substances 0.000 title abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97203407 | 1997-11-03 | ||
| PCT/EP1998/006998 WO1999022738A1 (en) | 1997-11-03 | 1998-10-27 | Compositions of lipid lowering agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20002279D0 NO20002279D0 (no) | 2000-04-28 |
| NO20002279L true NO20002279L (no) | 2000-04-28 |
Family
ID=8228898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002279A NO20002279L (no) | 1997-11-03 | 2000-04-28 | Sammensetninger av lipidsenkende midler |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6342245B1 (de) |
| EP (1) | EP1028730B1 (de) |
| JP (1) | JP2001521899A (de) |
| KR (2) | KR20010023661A (de) |
| CN (1) | CN1278175A (de) |
| AR (1) | AR013739A1 (de) |
| AT (1) | ATE216238T1 (de) |
| AU (1) | AU746890B2 (de) |
| BG (1) | BG104338A (de) |
| BR (1) | BR9814109A (de) |
| CA (1) | CA2307097A1 (de) |
| DE (1) | DE69804994D1 (de) |
| EE (1) | EE200000186A (de) |
| HU (1) | HUP0004139A3 (de) |
| NO (1) | NO20002279L (de) |
| NZ (1) | NZ503413A (de) |
| PL (1) | PL340305A1 (de) |
| SK (1) | SK5972000A3 (de) |
| WO (1) | WO1999022738A1 (de) |
| ZA (1) | ZA989997B (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03011784A (es) | 2001-06-22 | 2004-04-02 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros. |
| US20030059487A1 (en) * | 2001-09-21 | 2003-03-27 | Niazi Sarfaraz K. | Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals |
| US20040220240A1 (en) * | 2001-11-28 | 2004-11-04 | Pellegrini Cara A. | Method of increasing the extent of absorption of tizanidine |
| US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
| KR20060092255A (ko) | 2003-09-26 | 2006-08-22 | 알자 코포레이션 | 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법 |
| NZ546182A (en) * | 2003-09-26 | 2009-08-28 | Alza Corp | Controlled release formulations of opioid and nonopioid analgesics such as hydrocodone and acetaminophen |
| DE602004032149D1 (de) * | 2003-09-26 | 2011-05-19 | Alza Corp | Oros-push-stick für die kontrollierte abgabe von wirkstoffen |
| NZ546183A (en) * | 2003-09-26 | 2011-04-29 | Alza Corp | Controlled release formulations exhibiting an ascending rate of release |
| CN100563658C (zh) | 2003-11-14 | 2009-12-02 | 味之素株式会社 | 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂 |
| EP1737460A2 (de) * | 2004-04-09 | 2007-01-03 | Janssen Pharmaceutica N.V. | Intermittierendes dosierschema zur behandlung von übergewicht mit mtp-hemmern |
| WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
| US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| WO2006129193A2 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| CA2618264C (en) * | 2005-08-08 | 2015-11-24 | Abbott Gmbh & Co. Kg | Dosage forms with improved bioavailability |
| EP1938804A1 (de) * | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmazeutische Zubereitung enthaltend Neurokinin Antagonist |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| WO2010143199A1 (en) | 2009-06-11 | 2010-12-16 | Suven Nishtaa Pharma Private Limited | Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU697744C (en) * | 1994-10-27 | 2002-08-22 | Elanco Animal Health Ireland Limited | Apolipoprotein-B synthesis inhibitors |
| US5521186A (en) * | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
-
1998
- 1998-10-27 DE DE69804994T patent/DE69804994D1/de not_active Expired - Lifetime
- 1998-10-27 NZ NZ503413A patent/NZ503413A/en unknown
- 1998-10-27 EP EP98954483A patent/EP1028730B1/de not_active Expired - Lifetime
- 1998-10-27 BR BR9814109-0A patent/BR9814109A/pt not_active IP Right Cessation
- 1998-10-27 KR KR1020007002314A patent/KR20010023661A/ko not_active Withdrawn
- 1998-10-27 JP JP2000518671A patent/JP2001521899A/ja not_active Withdrawn
- 1998-10-27 EE EEP200000186A patent/EE200000186A/xx unknown
- 1998-10-27 AT AT98954483T patent/ATE216238T1/de not_active IP Right Cessation
- 1998-10-27 WO PCT/EP1998/006998 patent/WO1999022738A1/en not_active Ceased
- 1998-10-27 CA CA002307097A patent/CA2307097A1/en not_active Abandoned
- 1998-10-27 CN CN98810808A patent/CN1278175A/zh active Pending
- 1998-10-27 US US09/530,170 patent/US6342245B1/en not_active Expired - Fee Related
- 1998-10-27 KR KR1020007002383A patent/KR20010023729A/ko not_active Ceased
- 1998-10-27 PL PL98340305A patent/PL340305A1/xx unknown
- 1998-10-27 HU HU0004139A patent/HUP0004139A3/hu unknown
- 1998-10-27 AU AU11576/99A patent/AU746890B2/en not_active Ceased
- 1998-10-27 SK SK597-2000A patent/SK5972000A3/sk unknown
- 1998-11-02 AR ARP980105502A patent/AR013739A1/es not_active Application Discontinuation
- 1998-11-02 ZA ZA9809997A patent/ZA989997B/xx unknown
-
2000
- 2000-04-14 BG BG104338A patent/BG104338A/xx unknown
- 2000-04-28 NO NO20002279A patent/NO20002279L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1028730B1 (de) | 2002-04-17 |
| EP1028730A1 (de) | 2000-08-23 |
| NO20002279D0 (no) | 2000-04-28 |
| SK5972000A3 (en) | 2000-12-11 |
| HUP0004139A3 (en) | 2002-03-28 |
| BR9814109A (pt) | 2000-10-03 |
| JP2001521899A (ja) | 2001-11-13 |
| AU746890B2 (en) | 2002-05-02 |
| US6342245B1 (en) | 2002-01-29 |
| EE200000186A (et) | 2001-04-16 |
| AR013739A1 (es) | 2001-01-10 |
| BG104338A (en) | 2000-12-29 |
| KR20010023729A (ko) | 2001-03-26 |
| CN1278175A (zh) | 2000-12-27 |
| WO1999022738A1 (en) | 1999-05-14 |
| CA2307097A1 (en) | 1999-05-14 |
| AU1157699A (en) | 1999-05-24 |
| ATE216238T1 (de) | 2002-05-15 |
| DE69804994D1 (de) | 2002-05-23 |
| NZ503413A (en) | 2001-06-29 |
| PL340305A1 (en) | 2001-01-29 |
| ZA989997B (en) | 2000-05-02 |
| HUP0004139A2 (hu) | 2002-02-28 |
| KR20010023661A (ko) | 2001-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Darrah et al. | Rheumatoid arthritis and citrullination | |
| Sesay et al. | Enzymatic extraction of activated sludge extracellular polymers and implications on bioflocculation | |
| Chi et al. | Purification and identification of three novel antioxidant peptides from protein hydrolysate of bluefin leatherjacket (Navodon septentrionalis) skin | |
| Wang et al. | Whole peptidoglycan extracts from the Lactobacillus paracasei subsp. paracasei M5 strain exert anticancer activity in vitro | |
| MY123827A (en) | Antifungal compositions with improved bioavailability | |
| O'Sullivan et al. | Bioactivity of bovine lung hydrolysates prepared using papain, pepsin, and Alcalase | |
| Li et al. | Polysaccharide from ziyang selenium-enriched green tea prevents obesity and promotes adipose thermogenesis via modulating the gut microbiota | |
| RU94045855A (ru) | Производные пергидроизоиндола, способы их получения и содержащие их фармацевтические композиции | |
| AP2002002621A0 (en) | Pharmaceutical compositions of glycogen phosphorylase inhibitors | |
| ES2086377T3 (es) | Procedimiento para tratar o revestir un sustrato con una composicion acuosa y uso de dichas composiciones. | |
| Vail et al. | Ultra-Low Dispersity Poly (vinyl alcohol) Reveals Significant Dispersity Effects on Ice Recrystallization Inhibition Activity | |
| Zeng et al. | Recovery and identification bioactive peptides from protein isolate of Spirulina platensis and their in vitro effectiveness against oxidative stress‐induced erythrocyte hemolysis | |
| ES2172006T3 (es) | Composiciones farmaceuticas que contienen parthenium integrifolium o partes de la misma o un extracto o componente de la misma, uso de dicho material de planta para la preparacion de ciertos medicamentos y procedimiento de preparacion de un extracto de parthenium integrifolium. | |
| Nworu et al. | Immunomodulatory and immunorestorative activities of β-d-glucan-rich extract and polysaccharide fraction of mushroom, Pleurutus tuberregium | |
| Lawson et al. | Immunomodulation of murine collagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculus | |
| Li et al. | 2'‐Fucosyllactose attenuates aging‐related metabolic disorders through modulating gut microbiome‐T cell axis | |
| Fernández‐Tomé et al. | Lunasin peptide is a modulator of the immune response in the human gastrointestinal tract | |
| BG104338A (en) | Composition of lipid-reducing forms | |
| Decker et al. | Nucleosomes induce lymphocyte necrosis | |
| Liu et al. | Interaction of the biosurfactant, surfactin with betaines in aqueous solution | |
| Xie et al. | Dual regulatory effects of gut microbiota and their metabolites in rheumatoid arthritis: balancing pathogenic and protective mechanisms | |
| Mykhailenko et al. | The comparative analysis of carboxylic acid composition of four Iris species from Ukraine | |
| GB2409645A (en) | Flower essence-containing medicaments | |
| Giosafatto et al. | Extraction and characterization of foeniculum vulgare pectins and their use for preparing biopolymer films in the presence of phaseolin protein | |
| Labat et al. | Wheat gluten phenolic acids: occurrence and fate upon mixing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |